Acorda Therapeutics Stock Price, News & Analysis (NASDAQ:ACOR)

$27.20 2.20 (8.80 %)
(As of 01/22/2018 03:09 AM ET)
Previous Close$25.00
Today's Range$26.60 - $28.85
52-Week Range$13.60 - $33.00
Volume3.99 million shs
Average Volume1.16 million shs
Market Capitalization$1.27 billion
P/E Ratio-22.48
Dividend YieldN/A
Beta1.58

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorBio Therapeutic Drugs
SymbolNASDAQ:ACOR
CUSIP00484M10
Phone+1-914-3474300

Debt

Debt-to-Equity Ratio0.49%
Current Ratio2.77%
Quick Ratio2.40%

Price-To-Earnings

Trailing P/E Ratio-22.4793388429752
Forward P/E Ratio1,360.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$519.60 million
Price / Sales2.45
Cash FlowN/A
Price / CashN/A
Book Value$14.40 per share
Price / Book1.89

Profitability

Trailing EPS($1.21)
Net Income$-34,610,000.00
Net Margins-10.25%
Return on Equity-8.18%
Return on Assets-4.15%

Miscellaneous

Employees597
Outstanding Shares46,750,000

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) posted its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.69 by $0.26. The biopharmaceutical company had revenue of $141.07 million for the quarter, compared to analysts' expectations of $150.64 million. Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The business's revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.04) earnings per share. View Acorda Therapeutics' Earnings History.

When will Acorda Therapeutics make its next earnings announcement?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Acorda Therapeutics.

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2018?

13 brokerages have issued twelve-month target prices for Acorda Therapeutics' stock. Their forecasts range from $13.00 to $31.00. On average, they expect Acorda Therapeutics' share price to reach $20.33 in the next twelve months. View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • 1. According to Zacks Investment Research, "Acorda ’s key multiple sclerosis drug Ampyra is facing patent challenges in the United States. Hence, Acorda’s dependence on Ampyra for a major part of its revenue is concerning. Presently, Acorda is also working on strengthening its Parkinson’s pipeline by focusing on its late stage candidates Inbrija (formerly known as CVT-301) in its portfolio. However, Inbrija recently received a refusal to file letter from the FDA which is concerning as it would delay its commercial launch. Moreover, the company has its share of pipeline setbacks too with the recent discontinuation of a late stage PD candidate tozadenant. On the flip side, Ampyra showed sequential improvements. Also, the company is also working on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price has outperformed the industry in the last one year." (1/10/2018)
  • 2. HC Wainwright analysts commented, "Ziopharm’s CAR-T Programs Make a Splash at ASH; Reiterate Buy Ziopharm’s 2nd-gen CAR-T shows promise in early study. We attended the 2017 Annual Meeting of the American Society of Hematology (ASH) over the last weekend, where Ziopharm presented interim results from the ongoing Phase 1 clinical study in patients with CD19 + leukemia or lymphoma treated with Ziopharm’s second generation CD19 + CAR-T therapy. Recall, Ziopharm’s second generation CAR-T cells were manufactured using the company’s proprietary Sleeping Beauty (SB) transposon platform which shortens the manufacturing process to two weeks compared to the typical 3-4 weeks for currently approved CAR-T therapies, such as Kymriah from Novartis (NVS; not rated) and Yescarta from Gilead (GILD; not rated). The results from the Phase 1 study show that treatment of patients with relapsed/refractory leukemia or lymphoma (n = 8) resulted in a 50% complete response rate after one month of therapy." (12/14/2017)
  • 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)
  • 4. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:

  • Ron Cohen, President,Chief Executive Officer, Director (Age 62)
  • Richard P. Batycky Ph.D., Chief Technology Officer and Site Head (Age 49)
  • David Lawrence, Chief Business Operations, Principal Accounting Officer (Age 59)
  • Andrew R. Blight Ph.D., Chief Scientific Officer (Age 66)
  • Jane Wasman J.D., President - International, General Counsel, Corporate Secretary (Age 61)
  • Burkhard Blank M.D., Chief Medical Officer (Age 62)
  • Andrew Hindman, Chief Business Development Officer (Age 44)
  • Lauren M. Sabella, Chief Commercial Officer (Age 56)
  • Barry E. Greene, Independent Director (Age 53)
  • Peder K. Jensen M.D., Independent Director (Age 62)

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.65%), Convergence Investment Partners LLC (0.11%) and Acadian Asset Management LLC (0.05%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Who sold Acorda Therapeutics stock? Who is selling Acorda Therapeutics stock?

Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Convergence Investment Partners LLC. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence and Lorin Randall. View Insider Buying and Selling for Acorda Therapeutics.

Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?

Acorda Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of Acorda Therapeutics stock can currently be purchased for approximately $27.20.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $1.27 billion and generates $519.60 million in revenue each year. The biopharmaceutical company earns $-34,610,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Acorda Therapeutics employs 597 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 Saw Mill River Rd, ARDSLEY, NY 10502-2605, United States. The biopharmaceutical company can be reached via phone at +1-914-3474300.


MarketBeat Community Rating for Acorda Therapeutics (ACOR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  574
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acorda Therapeutics (NASDAQ:ACOR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.112.33
Ratings Breakdown: 2 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.33$20.77$23.25$24.67
Price Target Upside: 18.83% downside2.49% downside12.76% downside20.62% upside

Acorda Therapeutics (NASDAQ:ACOR) Consensus Price Target History

Price Target History for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ:ACOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018HC WainwrightReiterated RatingBuy -> Buy$34.00 -> $31.00MediumView Rating Details
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLowView Rating Details
11/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$22.00LowView Rating Details
11/17/2017CowenReiterated RatingBuy$30.00N/AView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetHold$26.00 -> $17.00N/AView Rating Details
11/16/2017Raymond James FinancialDowngradeMarket Perform -> Underperform$7.00 -> $13.00N/AView Rating Details
11/16/2017Stifel NicolausDowngradeBuy -> Hold$26.00 -> $15.00N/AView Rating Details
11/15/2017Leerink SwannLower Price TargetMarket Perform$18.00N/AView Rating Details
11/15/2017OppenheimerSet Price TargetHold$18.00N/AView Rating Details
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$18.00 -> $16.00N/AView Rating Details
11/9/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
11/1/2017Jefferies GroupBoost Price TargetHold$22.00 -> $25.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingSell -> Sell$20.00N/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Acorda Therapeutics (NASDAQ:ACOR) Earnings History and Estimates Chart

Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$1.00N/AView Earnings Details
10/31/2017Q3 2017$0.69$0.43$150.64 million$141.07 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.13$0.29$139.81 million$139.40 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
11/1/2010Q3 2010($0.12)$0.31ViewN/AView Earnings Details
8/3/2010Q2 2010($0.46)($0.18)ViewN/AView Earnings Details
4/30/2010Q1 2010($0.54)($0.56)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.60)($0.59)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.59)($0.52)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.54)($0.62)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.55)($0.50)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.52)($0.54)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.47)($0.53)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.47)($0.58)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.41)($0.45)ViewN/AView Earnings Details
2/11/2008Q4 2007($0.31)($0.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Acorda Therapeutics (NASDAQ:ACOR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.30$0.69$0.50
Q2 20182$0.49$0.84$0.67
Q3 20182($1.28)($0.10)($0.69)
Q4 20182($1.35)($0.65)($1.00)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Acorda Therapeutics (NASDAQ:ACOR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Acorda Therapeutics (NASDAQ ACOR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2017Burkhard BlankInsiderSell11,050$20.53$226,856.5033,150View SEC Filing  
10/9/2017David LawrenceInsiderSell250$25.40$6,350.00View SEC Filing  
8/29/2017Scopia Capital Management LpMajor ShareholderBuy766,201$19.23$14,734,045.23View SEC Filing  
8/1/2017Barry E GreeneDirectorSell10,000$21.57$215,700.0010,000View SEC Filing  
7/31/2017Lorin RandallDirectorSell10,000$21.66$216,600.0010,000View SEC Filing  
6/16/2017Ron CohenInsiderBuy20,000$16.95$339,000.00511,648View SEC Filing  
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.0046,123View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00519,860View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.9045,916View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.008,952View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00105,021View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00109,271View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.009,702View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.381,086View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.6049,670View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.841,488View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10100,124View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.5214,378View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00108,579View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.389,202View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.0014,378View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.4432,148View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00400,550View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.0071,659View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.0041,677View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.5098,097View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00412,400View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.5071,659View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.5712,403View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.4032,527View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00105,459View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00478,868View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acorda Therapeutics (NASDAQ ACOR) News Headlines

Source:
DateHeadline
Acorda Therapeutics Inc (ACOR) Given Average Rating of "Hold" by AnalystsAcorda Therapeutics Inc (ACOR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 20 at 5:38 PM
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors - MarketWatchAcorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors - MarketWatch
www.marketwatch.com - January 20 at 7:24 AM
Form 8-K/A ACORDA THERAPEUTICS INC For: Jan 19 - StreetInsider.comForm 8-K/A ACORDA THERAPEUTICS INC For: Jan 19 - StreetInsider.com
www.streetinsider.com - January 20 at 7:24 AM
Heres Why Acorda Therapeutics Inc. Stock Is Surging TodayHere's Why Acorda Therapeutics Inc. Stock Is Surging Today
www.fool.com - January 19 at 1:53 PM
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitorsAcorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors
www.marketwatch.com - January 19 at 9:13 AM
Form 8-K/A ACORDA THERAPEUTICS INC For: Jan 19Form 8-K/A ACORDA THERAPEUTICS INC For: Jan 19
www.streetinsider.com - January 19 at 9:13 AM
Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACORKessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR
finance.yahoo.com - January 17 at 11:36 AM
FINAL SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018FINAL SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018
finance.yahoo.com - January 17 at 11:36 AM
Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACORKessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR
finance.yahoo.com - January 17 at 11:36 AM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - January 16 at 3:22 PM
DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACORDEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - January 16 at 3:22 PM
IMPORTANT STOCKHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline NearsIMPORTANT STOCKHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline Nears
finance.yahoo.com - January 15 at 3:22 PM
ACOR UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018ACOR UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - January 15 at 3:22 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACORSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - January 14 at 3:22 PM
Stock Traders Buy Large Volume of Acorda Therapeutics Call Options (ACOR)Stock Traders Buy Large Volume of Acorda Therapeutics Call Options (ACOR)
www.americanbankingnews.com - January 14 at 3:40 AM
ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in ... - GlobeNewswire (press release)ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in ... - GlobeNewswire (press release)
globenewswire.com - January 13 at 7:53 AM
Traders Buy High Volume of Put Options on Acorda Therapeutics (ACOR)Traders Buy High Volume of Put Options on Acorda Therapeutics (ACOR)
www.americanbankingnews.com - January 13 at 2:04 AM
ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in Class Action – ACORACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in Class Action – ACOR
finance.yahoo.com - January 12 at 3:21 PM
IMPORTANT SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Shareholders That Important Deadline NearsIMPORTANT SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Shareholders That Important Deadline Nears
finance.yahoo.com - January 12 at 3:21 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - January 11 at 3:23 PM
Acordas Shares Down on Disappointing Ampyra View for 2018Acorda's Shares Down on Disappointing Ampyra View for 2018
www.zacks.com - January 10 at 3:23 PM
Acordas Shares Down on Disappointing Ampyra View for 2018 - NasdaqAcorda's Shares Down on Disappointing Ampyra View for 2018 - Nasdaq
www.nasdaq.com - January 10 at 7:58 AM
Acorda Therapeutics (ACOR) Announces 2017 AMPYRA Net Sales and 2018 Financial Guidance - StreetInsider.comAcorda Therapeutics (ACOR) Announces 2017 AMPYRA Net Sales and 2018 Financial Guidance - StreetInsider.com
www.streetinsider.com - January 9 at 3:22 PM
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Acorda Therapeutics, Inc. to Contact the FirmFINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Acorda Therapeutics, Inc. to Contact the Firm
finance.yahoo.com - January 9 at 3:22 PM
Acorda Therapeutics (ACOR) Earns Hold Rating from JPMorgan Chase & Co.Acorda Therapeutics (ACOR) Earns Hold Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - January 9 at 11:22 AM
ACOR EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018ACOR EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - January 8 at 3:26 PM
Kessler Topaz Meltzer & Check, LLP Reminds Acorda Therapeutics, Inc. Shareholders of Important Deadline in Class Action LawsuitKessler Topaz Meltzer & Check, LLP Reminds Acorda Therapeutics, Inc. Shareholders of Important Deadline in Class Action Lawsuit
finance.yahoo.com - January 8 at 11:06 AM
Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare ConferenceAcorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 11:06 AM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Shareholders That Important Deadline NearsSHAREHOLDER ALERT: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Shareholders That Important Deadline Nears
finance.yahoo.com - January 8 at 11:06 AM
Investors Are Undervaluing Acorda Therapeutics Inc (NASDAQ:ACOR) By 38.11%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing Acorda Therapeutics Inc (NASDAQ:ACOR) By 38.11%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - January 8 at 11:06 AM
Acorda Therapeutics, Inc. (ACOR) Expected to Post Quarterly Sales of $178.15 MillionAcorda Therapeutics, Inc. (ACOR) Expected to Post Quarterly Sales of $178.15 Million
www.americanbankingnews.com - January 8 at 10:30 AM
BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing SourcesBRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources
www.reuters.com - January 7 at 3:33 PM
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with  Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ACORSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ACOR
feeds.benzinga.com - January 6 at 8:56 AM
Acorda Therapeutics Exploring a Potential Sale - Wall Street JournalAcorda Therapeutics Exploring a Potential Sale - Wall Street Journal
www.wsj.com - January 6 at 7:58 AM
[$$] Acorda Therapeutics Exploring a Potential Sale[$$] Acorda Therapeutics Exploring a Potential Sale
finance.yahoo.com - January 6 at 7:58 AM
STOCKHOLDER ALERT: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline NearsSTOCKHOLDER ALERT: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline Nears
finance.yahoo.com - January 6 at 7:58 AM
Acorda Therapeutics (ACOR) and ProQR Therapeutics (PRQR) Head-To-Head ContrastAcorda Therapeutics (ACOR) and ProQR Therapeutics (PRQR) Head-To-Head Contrast
www.americanbankingnews.com - January 5 at 7:14 PM
Acorda Therapeutics reportedly exploring potential saleAcorda Therapeutics reportedly exploring potential sale
www.cnbc.com - January 5 at 4:56 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - January 4 at 3:22 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOREQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - January 4 at 3:22 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Juno Therapeutics, Acorda Therapeutics, Lexicon ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Juno Therapeutics, Acorda Therapeutics, Lexicon ... - PR Newswire (press release)
www.prnewswire.com - January 4 at 7:40 AM
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Acorda Therapeutics, Inc. Shareholders - GlobeNewswire (press release)Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Acorda Therapeutics, Inc. Shareholders - GlobeNewswire (press release)
globenewswire.com - January 3 at 11:08 AM
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Acorda Therapeutics, Inc. ShareholdersKessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Acorda Therapeutics, Inc. Shareholders
finance.yahoo.com - January 3 at 11:08 AM
Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 3:22 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline - January 17, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - December 28 at 5:03 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACORINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - December 27 at 3:12 PM
Acorda Therapeutics to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release)Acorda Therapeutics to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release)
www.businesswire.com - December 26 at 6:22 PM
Acorda Therapeutics, Inc. (ACOR) Given Average Recommendation of "Hold" by AnalystsAcorda Therapeutics, Inc. (ACOR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 26 at 4:39 PM
Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed against Acorda Therapeutics, Inc.Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed against Acorda Therapeutics, Inc.
finance.yahoo.com - December 26 at 1:05 PM
Acorda Therapeutics Inc (NASDAQ:ACOR): Earnings Expected To Remain SubduedAcorda Therapeutics Inc (NASDAQ:ACOR): Earnings Expected To Remain Subdued
finance.yahoo.com - December 26 at 1:05 PM

SEC Filings

Acorda Therapeutics (NASDAQ:ACOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acorda Therapeutics (NASDAQ:ACOR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acorda Therapeutics (NASDAQ ACOR) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.